Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunologic response to the survivin-derived multi-epitope vaccine EMD640744 in patients with advanced solid tumors.
Lennerz V, Gross S, Gallerani E, Sessa C, Mach N, Boehm S, Hess D, von Boehmer L, Knuth A, Ochsenbein AF, Gnad-Vogt U, Zieschang J, Forssmann U, Woelfel T, Kaempgen E. Lennerz V, et al. Among authors: gallerani e. Cancer Immunol Immunother. 2014 Apr;63(4):381-94. doi: 10.1007/s00262-013-1516-5. Epub 2014 Feb 2. Cancer Immunol Immunother. 2014. PMID: 24487961 Free PMC article. Clinical Trial.
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. Gallerani E, et al. Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Eur J Cancer. 2013. PMID: 23058787 Review.
Short Peptide Vaccine Induces CD4+ T Helper Cells in Patients with Different Solid Cancers.
Gross S, Lennerz V, Gallerani E, Mach N, Böhm S, Hess D, von Boehmer L, Knuth A, Ochsenbein A, Gnad-Vogt U, Forssmann U, Woelfel T, Kaempgen E. Gross S, et al. Among authors: gallerani e. Cancer Immunol Res. 2016 Jan;4(1):18-25. doi: 10.1158/2326-6066.CIR-15-0105. Epub 2015 Nov 12. Cancer Immunol Res. 2016. PMID: 26563311 Clinical Trial.
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin given every three weeks in patients with advanced solid tumors.
Sessa C, Del Conte G, Christinat A, Cresta S, Perotti A, Gallerani E, Lardelli P, Kahatt C, Alfaro V, Iglesias JL, Fernández-Teruel C, Gianni L. Sessa C, et al. Among authors: gallerani e. Invest New Drugs. 2013 Oct;31(5):1236-43. doi: 10.1007/s10637-013-9942-y. Epub 2013 Mar 7. Invest New Drugs. 2013. PMID: 23467812 Clinical Trial.
76 results